---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-134618"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:12:41.611849+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# ORIC provides rinzimetostat Phase 1b dose optimization update

## Summary
- Update covers dose optimization data from Phase 1b trial of rinzimetostat (ORIC-944).
- No numerical results or conclusions are disclosed in the 8-K filing itself.
- Full data is included in the attached presentation (Exhibit 99.1) dated March 31, 2026.

## SEC filing metadata
- accession: 0001193125-26-134618
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/0001193125-26-134618-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-134618
- JSON: https://secwatch.observer/filing/0001193125-26-134618.json
- Plain text: https://secwatch.observer/filing/0001193125-26-134618.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.